Want to see LBRX full AI Analyst Report?
LBRX Stock Chart & Stats
$47.10
--
Market closed
$47.10
--
Day’s Range― - ―
52-Week Range$14.32 - $50.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)424.48K
Market Cap
$1.28B
Enterprise Value$655.55M
Total Cash (Recent Filing)$327.79M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 05, 2026EPS Estimate
-1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding32,259,174
10 Day Avg. Volume449,593
30 Day Avg. Volume424,482
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.66K
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$61.44Price Target Upside30.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetThe sharp improvement in equity and very low leverage provide greater financial flexibility than in prior years. This stronger solvency position can support continued clinical investment and reduce near-term balance-sheet pressure while the company advances toward potential product commercialization.
Expanded Funding For Pipeline DevelopmentThe financing materially increases resources for late-stage development and broadens the potential application set for LB-102. Funding multiple indications can improve the company’s strategic options and sustain research activity through important clinical milestones over the next several quarters.
Experienced Leadership Ahead Of MilestonesAdding a senior clinical leader with relevant neuropsychiatric and regulatory experience strengthens execution capability as NOVA-2 approaches topline results. Her background may support development, regulatory planning, and preparation for a potential transition toward commercialization.
Bears Say
No Revenue TractionThe absence of revenue means the business has not yet demonstrated commercial demand or an internally funded operating model. Until a product generates sales, progress remains dependent on clinical success and continued access to capital, leaving earnings power unproven over the medium term.
Persistent Operating Cash BurnRecurring negative operating and free cash flow shows that ongoing activities consume substantial cash rather than financing themselves. Even with improved burn in 2025, continued investment without revenue increases the need to preserve liquidity and secure additional funding as trials progress.
Reliance On Financing And Dilution RiskDependence on external capital can constrain strategic flexibility if funding conditions weaken and may require additional equity issuance before revenue begins. Such financing can dilute existing holders, while the need to repeatedly raise capital underscores the company’s unproven commercial economics.
LB Pharmaceuticals, Inc. News
LBRX FAQ
What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?
LB Pharmaceuticals, Inc. lowest stock price was $14.32 and its highest was $50.16 in the past 12 months.
What is LB Pharmaceuticals, Inc.’s market cap?
LB Pharmaceuticals, Inc.’s market cap is $1.28B.
When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?
LB Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 8 days.
How were LB Pharmaceuticals, Inc.’s earnings last quarter?
LB Pharmaceuticals, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$0.804 by -$0.906.
Is LB Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued.
Does LB Pharmaceuticals, Inc. pay dividends?
LB Pharmaceuticals, Inc. does not currently pay dividends.
What is LB Pharmaceuticals, Inc.’s EPS estimate?
LB Pharmaceuticals, Inc.’s EPS estimate is -1.62.
How many shares outstanding does LB Pharmaceuticals, Inc. have?
LB Pharmaceuticals, Inc. has 32,259,174 shares outstanding.
What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?
LB Pharmaceuticals, Inc. reported an EPS of -$1.71 in its last earnings report, missing expectations of -$0.804. Following the earnings report the stock price went down -1.134%.
Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LB Pharmaceuticals, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.44 (30.46% Upside)
$61.44 (30.46% Upside)
Blogger Sentiment
Bullish
LBRX Sentiment 67%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.33%
12-Months-Change
Fundamentals
Return on Equity
-25.91%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LB Pharmaceuticals, Inc.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX Stock 12 Month Forecast
Average Price Target
$61.44
▲(30.46% Upside)
Technical Analysis
Ownership Overview
14.77%
Insiders
11.96% Mutual Funds
0.09% Other Institutional Investors
64.45% Public Companies and
Individual Investors